81 related articles for article (PubMed ID: 33840014)
1. Biomarkers and Strategies for Early Detection of Ovarian Cancer.
Bast RC; Lu Z; Han CY; Lu KH; Anderson KS; Drescher CW; Skates SJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2504-2512. PubMed ID: 33051337
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.
Englisz A; Smycz-Kubańska M; Mielczarek-Palacz A
Diagnostics (Basel); 2024 Apr; 14(9):. PubMed ID: 38732363
[TBL] [Abstract][Full Text] [Related]
3. The Progress of the Specific and Rapid Genetic Detection Methods for Ovarian Cancer Diagnosis and Treatment.
Dong K; Zhang W; Cheng S; Shu W; Zhao R; Wang H
Technol Cancer Res Treat; 2022; 21():15330338221114497. PubMed ID: 36062718
[TBL] [Abstract][Full Text] [Related]
4. Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research.
Gadducci A; Cosio S
Anticancer Res; 2022 Sep; 42(9):4207-4216. PubMed ID: 36039417
[TBL] [Abstract][Full Text] [Related]
5. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
[TBL] [Abstract][Full Text] [Related]
6. PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer.
Elsharkawi SM; Elkaffash D; Moez P; El-Etreby N; Sheta E; Taleb RSZ
BMC Cancer; 2023 Jan; 23(1):89. PubMed ID: 36698136
[TBL] [Abstract][Full Text] [Related]
7. Molecular Management of High-Grade Serous Ovarian Carcinoma.
Punzón-Jiménez P; Lago V; Domingo S; Simón C; Mas A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430255
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer screening: Current status and future directions.
Nash Z; Menon U
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169
[TBL] [Abstract][Full Text] [Related]
9. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
[TBL] [Abstract][Full Text] [Related]
10. Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.
Srivastava A; Gupta A; Patidar S
Clin Transl Oncol; 2021 Oct; 23(10):1967-1978. PubMed ID: 33840014
[TBL] [Abstract][Full Text] [Related]
11. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
14. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
